Princess Halm, Sumana Kondle*, Derek Sun
Chronic hepatitis C is one of the most common causes of liver disease and cancer world-wide. 20% of cases of chronic hepatitis are at high risk to develop cirrhosis and amongst them there is a 4%-5% annual incidence rate of hepatocellular carcinoma. Around the world, HCV infection is one of the leading causes of permanent liver damage, and related deaths, especially due to end-stage liver disease and hepatocellular carcinoma. Emerging data suggest that viral cure reduces, but does not eliminate the risk for hepatocellular carcinoma (HCC) development. The question that this paper seeks to find the answer to is, are there any In vitro or in vivo trials, currently being executed to discover a hepatitis C vaccine for those at risk, or already afflicted with, hepatitis C. If so, what is the perceived plausibility that an effective one is soon in the making? To find appropriate literature to assess, 70 articles were originally solicited, leaving exactly twelve remaining for data analysis through tabular format. Of these, the most promising trial vaccine was found to be a dendritic cell vaccine currently being created and tested by the Russian Academy of Sciences. The future for hepatitis C vaccine development looks bright, but there are still many continued challenges to the development of a perfectly potent therapy.
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi